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Objective: This study was undertaken to define total long-term outcome achievable with invasive treatment, ie,
endovascular or surgical, in patients with claudication with infrainguinal lesions. Priority in primary treatment was given
to percutaneous transluminal angioplasty.
Methods: Data were analyzed for 233 consecutive patients with claudication in whom primary infrainguinal revascular-
ization was performed in 304 limbs between 1989 and 1992. Patients were followed-up to May 2001 (mean, 81 months).
Treatment included primary endovascular therapy when applicable (n  272 limbs) or primary surgical treatment (n 
32; 10.5%). Type of further revascularization, if required, was selected on an individual basis for each patient. All
procedures performed because of limb ischemia were recorded. Clinical outcome at the end of follow-up was compared
with the preoperative condition. Cumulative primary, secondary, and total patency rates and development of chronic
critical ischemia (CCI) were defined. Total patency reflects the ultimate achievable benefit of invasive treatment and refers
to patency maintained at the primarily treated segment by means of any invasive (endovascular or surgical) therapy,
including potential crossover to another treatment group.
Results: A mean of 2 (median, 1) operations per limb were performed during follow-up. No additional operations were
needed in 50.3% (n  153) of limbs. Fontaine classification at the end of the study was better compared with the
preoperative value (P < .0005). Crossover between endovascular and surgical treatment was recorded in 21.1% (n  64)
of limbs. At 5 years, primary, secondary, and total patency rates (plus or minus standard error of estimate [SEE]) were
27%  3%, 45%  3%, and 61%  3%, respectively, and at 10 years these rates were 16%  3%, 27%  3%, and 41%  3%.
CCI developed in 37 limbs (12.2%), of which 15 (41%) had been treated with endovascular methods only. Type II
diabetes and hypertension were statistically significant predictors of increased risk for CCI.
Conclusion: Combining endovascular and surgical methods when necessary improved total outcome of invasive infrain-
guinal treatment of claudication. Crossover between endovascular and surgical treatment was required in 21% of limbs
over the long term. (J Vasc Surg 2003;37:808-15.)
Endovascular and surgical treatments have been used
to treat lifestyle-limiting claudication when conservative
therapy is inadequate. There are numerous reports on the
outcome of both endovascular and surgical procedures in
treatment of infrainguinal atherosclerotic lesions in patients
with claudication.1-6 Each of these primary treatment op-
tions has benefits and disadvantages.4,6-14
The overall long-term outcome of invasive treatment of
claudication remains unclear, because crossover from endo-
vascular to surgical treatment or vice versa has been consid-
ered treatment failure and therefore an end point for fol-
low-up in existing reports. It is important to define the
outcome of individual procedures. However, in clinical
practice endovascular and surgical treatments are often
combined over time to achieve the best outcome, because
percutaneous transluminal angioplasty (PTA) and surgery
seem to be complementary rather than competitive thera-
peutic options.13 Do the long-term results of invasive treat-
ment with combined methods, when necessary, differ from
those reported for a single method?
The goal of this retrospective analysis was to define the
long-term outcome achievable in patients with claudication
treated with invasive methods including both endovascular
procedures and surgery. In our strategy for infrainguinal
revascularization to treat claudication, the emphasis was on
PTA. The role of crossover between endovascular and
surgical treatments was examined over 8 to 12 years of
follow-up. Patency rates, development of chronic critical
ischemia (CCI) with subsequent amputation, and patient
survival data are presented along with their determinants.
METHODS
This study was performed in a university hospital be-
tween January 1989 and May 2001. Primary procedures
were performed between 1989 and 1992. PTA was used
primarily if lesions were judged to be technically amenable
to endovascular treatment at a joint meeting of interven-
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tional radiologists and vascular surgeons. In general these
lesions had no heavy calcification, the length of stenosis was
20 cm or less, and length of occlusion was 15 cm or less.
Proximal lesions suitable for endarterectomy or profunda-
plasty were treated surgically. Relative contraindications for
surgery and absence of good quality saphenous vein favored
use of PTA. Limbs in which previous infrainguinal revascu-
larization procedures had been performed; those with CCI,
defined as ischemic rest pain or tissue defect combined with
ankle systolic pressure 50 mm Hg or less15,16; and limbs
with main lesions in iliac vessels were excluded. Primary
procedures were performed for accepted clinical indications
in our hospital. Approval of the institutional ethical com-
mittee was obtained, and patients gave informed consent
for participation in follow-up examinations during the
study.
Patients were first seen by a vascular surgeon at the
outpatient clinic. Ankle/brachial index (ABI) at rest was
measured. A treadmill exercise test and digital subtraction
angiography of the aorta and runoff vessels were routinely
performed. Preoperative angiograms were used for scoring
the limbs according to number of arteries with hemody-
namically significant stenosis (50% diameter stenosis).
The theoretical maximum was 10 arteries, including vessels
from the common iliac artery to the crural arteries.17 Pre-
operative runoff was classified as good in limbs with two or
three patent calf vessels (50% stenosis of reference vessel
diameter) and poor in limbs with no or one patent calf
vessel.18
Endovascular procedures were performed in an angiog-
raphy suite. Lesions were routinely treated with a 5F con-
ventional balloon angioplasty catheter with the aid of
Glidewire (Terumo, Piscataway, NJ). Surgical techniques
conformed to standard principles. Autologous vein was
used in all bypass procedures if available. Primary failure
refers to technical failure or to demonstrated loss of patency
(ABI, duplex ultrasound scanning, angiography) in the
treated segment or bypass graft 24 hours after the proce-
dure. Primary failure data are included in outcome analyses.
Complications were classified according to recommended
reporting standards.19
Patient follow-up and long-term outcome. Fol-
low-up examinations were performed at 1, 3, 6, and 12
months after primary PTA and routinely at 1 month after
primary surgical treatment (PS). Patients who underwent
primary endovascular treatment (PE) were examined yearly
for up to 3 years, and additional visits for all patients were
arranged according to clinical necessity. Extensive fol-
low-up visits for all patients were made between 1997 and
1999. All follow-up visits included subjective history, clin-
ical examination, and determination of ABI. Duplex ultra-
sound scanning or angiography was performed in patients
with subjective or objective deterioration. Patient files were
reviewed for the last time in June or July 2001. Number of
total hospital days because of limb ischemia and number of
hospitalization periods, including for diagnostic studies,
were determined. Total outcome of invasive treatments of
lower limb ischemia was compared with the preoperative
condition according to Fontaine and Rutherford classifica-
tions. Information concerning repeat operations, hospital-
izations, complications, treatment outcome, development
of CCI, and amputation is considered complete because
relevant patient data from other hospitals were also re-
viewed at the end of the study.
Patency rates were defined according to the current
reporting standards19 using either ABI, Duplex ultrasound
scanning, or angiography. Limbs were considered lost to
follow-up after the last date of objective proof of patency or
limb salvage. Primary patency is uninterrupted patency at
the treated segment or graft, with either no procedure
performed or a similar endovascular or surgical procedure
performed to treat disease progression beyond the treated
segment or graft. If patency of the treated segment or graft
was maintained or restored with a procedure similar to PE
or PS, patency was considered secondary patency. Repeat
reconstructions were not included in primary or secondary
patency. Total patency is patency maintained at the primar-
ily treated segment by means of any invasive endovascular
or surgical procedure and includes limbs after potential
crossover to another treatment group (PE to PS or vice
versa) and all of their combinations. Therefore total pa-
tency reflects the ultimate achievable benefit of an invasive
treatment method. Indications for reinterventions were
objectively proved early recurrent obstruction, recurrence
of subjective symptoms due to recurrent obstruction dur-
ing follow-up, or development of CCI. Survival data are
considered complete because Statistics Finland records all
deaths of Finnish citizens.
Statistical analysis. Discrete variables in the study
groups were analyzed with the Pearson 2 test. The Mann-
Whitney U test and Student t test were used when appro-
priate for continuous variables. Sign test was used to com-
pare Fontaine grade at the end of the study with
preoperative grade. Stepwise multiple logistic regression
analysis was used to test variables associated with CCI
development. Survival analyses were constructed with the
life table method. Sex, age, type of primary operation (PE
or PS), hypertension, diabetes, hyperlipidemia, coronary
artery disease, cerebrovascular disease, renal insufficiency,
preoperative Fontaine classification, preoperative ABI,
number of diseased vessels in the treated limb, main treated
segment, total length of treated lesion, peripheral runoff,
primary failure, medication during follow-up, and history
of smoking were used as determinants in univariate analysis.
The statistical difference between survival curves was deter-
mined with the Wilcoxon test. Variables that reached sta-
tistical difference (P  .05) were used as covariates in the
stepwise Cox proportional hazards model. The level of
significance for inclusion both in the logistic regression
analysis and the Cox model was  .10, and for removal
from the model it was  .15. Odds ratios and 95% confi-
dence intervals (CI) were calculated for the significant
determinants in Cox multiple regression analyses. Statistical
analyses were performed with SPSS for Windows 9.0 (SPSS
Inc, Chicago, Ill) statistical software.
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RESULTS
The study population consisted of 233 consecutive
patients (304 limbs) who underwent infrainguinal endovas-
cular and/or surgical treatments of lifestyle-limiting clau-
dication (absolute walking distance 100 m or manifest
deficiency in occupational or recreational activities).
Mean  SD value for absolute preoperative walking dis-
tance was 150 79 m, and for ABI it was .65 .19. Patient
data are given in Table I. PE was used in 272 limbs (89.5%),
and PS was used in 32 limbs (10.5%). There were no
statistically significant differences in preoperative risk fac-
tors (smoking habits, coronary artery disease, hypertension,
diabetes, hyperlipidemia, cerebrovascular disease, renal in-
sufficiency) or in number of diseased vessels, preoperative
runoff, main treated segment, preoperative walking dis-
tance, or gender or age between the PE and PS groups.
However, treated lesions were significantly longer in the PS
group (Table II).
After primary PTA, stenting was performed in two
limbs and directional atherectomy in six limbs to make the
primary angiographic result acceptable. The primary failure
rate was 15.1% (n  46); all treatment failures were in the
PE group. All primary bypass procedures were performed
with either in situ or reversed autologous saphenous vein.
Distal anastomosis was made to crural arteries only if more
proximal vessels were not applicable. Distal anastomoses in
the 24 primary bypass procedures included 3 above the
knee (13%), 19 below the knee (79%), and 2 crural (8%).
Endarterectomy or profundaplasty was performed in 8
limbs. All patients were advised to take acetylsalicylic acid
(ASA; 250 mg) daily if there were no contraindications.
Almost 4 of 5 patients (79.8%) used continuous ASA
treatment. Another 6.9% received oral anticoagulation
therapy because of other medical conditions.
Clinical events. Mean duration of follow-up was 81
months (range, 1-146 months; median, 95 months), and
there was no difference between the PE or PS groups.
During the study 620 invasive procedures were performed
because of lower limb ischemia in the 304 treated limbs
(range, 1-10 per limb; mean, 2; median, 1). There was no
statistically significant difference in total number of invasive
procedures per limb between the PE and PS groups. Of the
316 repeated procedures, 52.8% (n  167) were endovas-
cular and 47.2% (n  149) were surgical. The mean num-
ber of total hospital days because of lower limb ischemia
was 8.5 (range, 1-64 days), and it was higher in the PS
group than in the PE group (mean, 15.7 vs 7.7; median, 12
vs 4) (P .0005). In the total population, mean number of
hospitalizations was 2.7 (range, 1-10). There was no statis-
tically significant difference in number of hospitalizations
because of limb ischemia between the PE and PS groups.
Treatment paths and crossover in PE and PS groups are
shown in Fig 1. No further operations were required during
follow-up in 50.3% (n  153) of the treated limbs: 50.7%
(n 138) in the PE group compared with 46.9% (n 15)
in the PS group (difference not significant). The length of
treated lesions (10 cm vs 10 cm) was not associated
with higher need for repeat operation in either the PE or PS
group (P  .19 and P  .31, respectively).
Fontaine classification at the end of the study was
statistically significantly better compared with the preoper-
ative value in the total study population and in the PE and
PS groups (all P values  .0005). The outcome in limbs
with preoperative Fontaine class 2B was significantly better
compared with the preoperative state (P  .0005; 71%
improved, 21% remained stable, 8% deteriorated), whereas
limbs with milder claudication (Fontaine class 2A) did not
have a statistically significant benefit from invasive treat-
ment (P .18). However, also in this subgroup more limbs
demonstrated improvement than deterioration (35% im-
proved, 42% remained stable, 23% deteriorated). The
length of treated lesions and type of primary treatment were
not determinants of late clinical outcome. Furthermore,
limbs with treated lesions longer than 10 cm improved
statistically significantly in both PE and PS groups, and
there was no difference between the treatment groups (P
.78). Improvement in Rutherford category was registered
in 77.6% of treated limbs at the end of the study (Appendix
I, online only).
Complications and 30-day mortality. Two minor
complications (minor hemorrhage, bradycardia) and two
major complications (pulmonary edema, retroperitoneal
hematoma requiring operative treatment) were associated
with diagnostic angiography. Fifteen minor complications
(4.9% of treated limbs) and 36 major complications (11.8%
of treated limbs) were associated with treatment. Major
complications were attributed to endovascular treatment in
Table I. Patient population and preoperative Fontaine
classification
Parameter n %
Patients 233
Men 169 72.5
Women 64 27.5
Treated limbs 304
Associated diseases at primary operation
Hyperlipidemia (fS-cholesterol 5.0 mmol/L or
fS-triglycerides 2.0 mmol/L)
184 79.0
Coronary artery disease (MI, CABG, AP, or
ischemia on ECG)
135 57.9
Hypertension (medication, or blood pressure
repeatedly 160/90 mm Hg)
131 56.2
Type II diabetes 79 33.9
Cerebrovascular disease (TIA or stroke) 41 17.6
Renal insufficiency (S-creatinine 150 mol/L) 4 1.7
Smoking habits
Current smoker or stopped 10 years ago 128 54.9
Stopped 10 years ago or never smoked 105 45.1
Preoperative Fontaine classification according to
treated limbs
Class 2A (claudication walking distance 200 m) 96 31.6
Class 2B (claudication walking distance 200 m) 208 68.4
Mean age of population was 66 years (range, 43-90 years) at the time of the
primary procedure. For statistical analyses two groups were created: 65
years, n  101; 65 years, n  132.
MI, Myocardial infarct; CABG, coronary artery bypass grafting; AP, angina
pectoris; ECG, electrocardiogram; TIA, transient ischemic attack.
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Fig 1. Treatment path of invasively treated claudication.
Table II. Diseased vessels and preoperative runoff in primary endovascular and primary surgical groups
Parameter
Total study
population
(n  304) PE (n  272) PS (n  32)
P (PE vs PS)n % n % n %
Number of diseased vessels
Mean 2.6 2.6 2.6 NS
Range 1-6 1-6 1-6
Total length of treated
lesions (cm)
.0005
Mean 8.7 7.9 15.8
Range 1-30 1-30 2-30
Number of limbs
according to total length
of treated lesions (cm)
10 224 73.7 210 77.2 14 43.7
10-20 52 17.1 46 16.9 6 18.8
20 28 9.2 16 5.9 12 37.5
Preoperative runoff
Mean 2.0 1.9 2.2 NS
Range 0-3 0-3 1-3
Main treated segment NS
Common femoral artery 8 5 3
Superficial femoral artery 257 230 27
Deep femoral artery 3 2 1
Popliteal artery 23 22 1
Tibiofibular trunk 5 5 0
Anterior tibial artery 5 5 0
Posterior tibial artery 2 2 0
Peroneal artery 1 1 0
Runoff was assessed as number of patent (50% diameter stenosis) crural vessels reaching the ankle.
PE, Primary endovascular procedure; PS, primary surgical procedure.
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15 instances (42%) and to surgical procedures in 21 in-
stances (58%). Of the 620 invasive therapeutic procedures
performed because of lower limb ischemia, 2.4% were
associated with minor complications and 5.8% with major
complications. Primary treatment led to 12 major compli-
cations, representing 32% of all major complications caused
by invasive treatment of limb ischemia; 7 of these were
caused by endovascular treatment, and 5 were caused by
surgical procedures (Appendix II, online only). Hence
2.6% of PE procedures were associated with major compli-
cation, compared with 15.6% of PS procedures. Treatment
of major complications required 21 invasive lower limb
procedures, representing 3.4% of all procedures performed
because of limb ischemia. No deaths were associated with
primary procedures, but 7 patients (3.0%) died as a result of
complications caused by repeated treatment of lower limb
ischemia. Five of these procedures were performed because
of CCI (Appendix II, online only). Fatal complications
were caused by endovascular treatment in 2 cases and by
surgical procedures in 5 cases.
Long-term success. At 1, 5, and 10 years, cumulative
primary patency rates ( SEE) in the total study population
were 51%  3%, 27%  3%, and 16%  3%, respectively;
secondary patency rates were 70%  3%, 45%  3%, and
27%  3%; and total patency rates were 80%  2%, 61% 
3%, and 41% 4%, respectively (Fig 2; Appendix III, online
only).
Among all tested variables, only type of primary proce-
dure (PE vs PS) proved to be a statistically significant
determinant of primary patency (P .003). At 1, 5, 8, and
10 years, primary patency rates ( SEE) in the PS group
were 76% 8%, 44% 10%, 28% 10%, and 17% 11%;
and in the PE group were 48% 3%, 25% 3%, 17% 3%,
and 16%  3%. Length of treated lesions (10 cm vs 10
cm) was not a statistically significant determinant of pri-
mary or total patency rate in the PE or PS groups. There
was no difference in total patency rate between the PE and
PS groups.
CCI and amputation. Altogether CCI developed in
37 limbs (12.2%), of which 41% (15 of 37) had been treated
solely with endovascular methods. Hence the incidence of
CCI development was 1.8% per year, and the time from the
primary operation until the development of CCI was on
average 61 months (range, 2-132 months). There were no
statistically significant differences between the PE and PS
groups. CCI developed in only one limb without repeat
operation. Type II diabetes and hypertension were inde-
pendent predictors of increased risk for CCI development
(Table III). There were 6 (2.0%) minor and 20 (6.6%)
major amputations, including repeat amputations. Four-
teen limbs (4.6%) were lost. Hence 38% of limbs in which
CCI developed required major amputation. Altogether,
4.8% of limbs in the PE group and 3.1% of limbs in the PS
group were lost (difference not significant).
Survival. One hundred eleven (47.6%) patients died.
Cardiovascular disease was the most common cause of
death (n  71, 64.0%). Cerebrovascular disease was the
cause of 12 deaths (10.8%), and cancer was responsible for
13 deaths (11.7%). At 1, 5, 10, and 12 years, cumulative
survival rate ( SEE) in the total study population was 97%
 1%, 82%  2%, 54%  3%, and 43%  5%, respectively.
According to stepwise Cox multiple regression analysis,
patients with diabetes, cerebrovascular disease, renal insuf-
ficiency, and poor runoff had decreased survival (Table IV).
DISCUSSION
Patients with claudication demonstrate statistically sig-
nificant improvement in walking distance and ABI at 19
Fig 2. Primary, secondary, and total patency rates in study population (SEE  .04 throughout follow-up).
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months after invasive treatment compared with conserva-
tive treatment.20 In a prospective, randomized study, only
invasive treatment (PS or PE) compared with supervised
exercise training or observation improved circulation in
patients with claudication at 1 year to an extent that led to
functional improvement in walking ability and maximum
exercise power.21 However, Whyman et al22 reported that
patients with mild to moderate claudication treated with
PTA had no statistically significant advantage in maximum
walking distance or ABI over patients with medical treat-
ment at 2 years.22 In the present study, Fontaine classifica-
tion was statistically significantly better at the end of mean
follow-up of 6 years 9 months than before the primary
intervention. Patients with severe claudication (preopera-
tive Fontaine class 2B) exhibited a clear benefit. Moreover,
among patients with less severe but lifestyle-limiting clau-
dication (Fontaine 2A), only 23% deteriorated during fol-
low-up. An 80% spontaneous improvement rate in claudi-
cation reported in the literature is based on historical series
in which peripheral arterial occlusive disease was not objec-
tively measured. In more recent series, the improvement
rate has been about 62%.23 The highest percentage of
spontaneous recovery has been recorded in patients with
mild symptoms. Our patients had severe (walking distance,
100 m) or lifestyle-limiting claudication that had not
responded to conservative treatment.
In our treatment strategy the emphasis was on PE,
which is in accord with the current consensus. Endovascu-
Table III. Determinants of development of chronic critical ischemia
Variable
Univariate analysis Multiple logistic regression analysis (stepwise)
P
Number of limbs with
CCI
P Odds ratio (95% CI)n %
Diabetes .0005 .0004 3.8 (1.8; 7.9)
No 13/197 6.6
Type II 24/107 22.4
Runoff .005 — — —
Good 18/199 9.0
Poor 19/105 18.1
Hypertension .004 .01 3.0 (1.3; 7.2)
No 7/124 5.6
Yes 30/180 16.7
CCI, Chronic critical ischemia; CI, confidence interval; good runoff with 2 or 3 patent crural vessels, poor runoff with no or 1 patent crural vessel.
Table IV. Patient survival: Results of univariate and Cox multiple regression analyses
Variable
Life table ( SEE) Cox multiple regression*
P 1 year 5 years 10 years P Odds ratio (95% CI)
Diabetes .0001 .0004 2.0 (1.4; 2.9)
No 99 (0.01) 88 (0.03) 63 (0.04)
Yes 92 (0.03) 68 (0.05) 38 (0.06)
Age (y) .0002
65 97 (0.02) 89 (0.03) 69 (0.05)
65 97 (0.01) 76 (0.04) 43 (0.05)
Cerebrovascular disease .02 .01 1.8 (1.1; 2.8)
No 97 (0.01) 84 (0.03) 58 (0.04)
Yes 95 (0.03) 71 (0.07) 39 (0.08)
Preoperative Fontaine classification .03 .06 1.5 (0.98; 2.4)
2A 99 (0.01) 88 (0.04) 67 (0.06)
2B 97 (0.01) 80 (0.03) 50 (0.04)
Renal insufficiency† .04 .02 4.0 (1.2; 12.9)
No 97 (0.01) 83 (0.03) 55 (0.03)
Yes 75 (0.22) 25 (0.22) —
Runoff‡ .04 .04 1.5 (1.0; 2.2)
Good 97 (0.01) 84 (0.03) 57 (0.04)
Poor 96 (0.02) 76 (0.05) 48 (0.06)
*Age was left out of the Cox multiple regression model because of its unquestioned effect on survival.
†Renal insufficiency, serum creatinine 150 mol/L.
‡Good runoff, 2 or 3 patent crural vessels; poor runoff, no or 1 patent crural vessels.
SEE, Standard error of estimate; CI, confidence interval.
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lar methods should be used as the primary invasive treat-
ment of claudication, and surgery may be considered if
conservative and endovascular methods are not possible or
fail.24 However, many of the lesions treated with PTA in
this study were longer than the current recommendations
suggest for endovascular treatment. It has been suggested
that the range of lesions treated with PTA should be
extended to include limbs with more extensive femoropop-
liteal disease.25 Preoperative risk factors and lesion profiles
were similar in the PE and PS groups despite the length of
treated segments, which were longer in the PS group.
Patients who undergo infrainguinal revascularization
because of claudication may require endovascular or surgi-
cal repeat operations over time because of restenosis, occlu-
sion of the bypass graft, or disease progression at a new
arterial site. Revision of vein graft stenosis with PTA in focal
lesions or with surgical methods in more extensive cases has
been associated with good results.26,27 If a surgical bypass
graft is required later after PTA, the nature of the graft is
unchanged by the preceding procedure.28 In this study,
almost half of all treated limbs required further invasive
treatment. Only 10.5% of the primary procedures, but as
many as 47.2% of repeat procedures, were surgical. On
average, there were 2 invasive procedures per limb. In a
previous study of infrainguinal bypass grafting with a max-
imum follow-up of 5 years, the average number of proce-
dures was 1.8 per limb.29 In that study, 30% of primary
grafts, excluding early repeat operations, required repeat
intervention. In a study with mean follow-up of 2.1 years,
19% of the limbs in which surgical revascularization had
been performed required vascular repeat operations.30
Crossover between endovascular and surgical treatment has
been reported in 16% of limbs during a follow-up of 19
months.20 In our study, crossover was required in 21% of
limbs, with similar numbers in the PE and PS groups. The
length of treated lesions did not predict need for repeat
operation in either the PE or the PS group.
To our knowledge, total long-term patency rates for
both endovascular and surgical methods have not been
reported previously. In endovascular series, secondary pa-
tency rates have been reported relatively seldom and have
included only repeated endovascular treatments and not
repeated surgeries.4,5,31-33 Total patency rates were clearly
superior to primary and secondary patency rates. The use of
combined invasive treatments, when necessary, produced
total patency rates 1.6 to 3.0 times higher than primary
patency rates and 1.1 to 1.7 times higher than secondary
patency rates. It should be noted that the repeat operation
policy for patients with claudication was conservative at our
hospital. Repeat operations were performed only in cases of
objectively proved early recurrent obstruction, recurrence
of subjective symptoms due to recurrent obstruction dur-
ing follow-up, or development of CCI. If repeat operations
had been performed in cases of objectively proved but
asymptomatic recurrent obstruction, the total patency rates
could have been higher. There was no difference in total
patency rate between the PE and PS groups.
According to the literature, the natural progression of
claudication to CCI in untreated populations has previ-
ously been 4.5% per year.34 In some patients with claudi-
cation CCI develops despite invasive treatment. In our
patients, progression to CCI was 1.8% per year, with CCI
developing during follow-up in 12.2% of limbs. It seems
that invasive treatment of claudication prevents develop-
ment of CCI over the long term or at least delays it. Invasive
treatment of claudication reduces the deterioration of ath-
erosclerotic lesions more than does conservative treat-
ment.22 Patients with diabetes or hypertension are at in-
creased risk for CCI.
The limitations of this study are lack of a conservatively
treated control population, its partly retrospective nature,
and the small number of patients in the PS group. How-
ever, the statistical analyses performed were appropriate,
and standard errors were within acceptable limits. Because
of the study design and the small number of limbs in the PS
group, comparisons between the PE and PS groups are not
completely firm. Sixty-five limbs were lost to follow-up for
objective patency, but the duration of follow-up needs to
be borne in mind here. The relatively short study period
with a long follow-up facilitates assessment of frequency of
repeat operations and development of CCI more reliably
than if more contemporary cases were included. Although
endovascular options have increased since the primary pro-
cedures in this study were performed, standard femoropop-
liteal PTA is still the most often used method for treatment
of claudication, as it was when the primary procedures were
performed. The concept of total patency is new. All acces-
sible invasive methods have been accepted as maintaining
total patency and infrainguinal circulation. The most im-
portant goals in invasive treatment of claudication are to
minimize symptoms, prevent development of CCI by keep-
ing the diseased infrainguinal segments patent, and treat
potential new lesions with clinical significance.
We conclude that combining endovascular and surgical
methods when necessary during follow-up improved the
long-term total outcome in invasive infrainguinal treatment
of claudication. Crossover between endovascular and sur-
gical treatment was required in 21% of limbs over the
long-term, regardless of the type of primary procedure. On
the basis of our results, selected lesions longer than 10 cm
also seem suitable for primary PTA in patients with claudi-
cation.
REFERENCES
1. Byrne J, Darling RC, Chang BB, Paty PSK, Kreienberg PB, Lloyd WE,
et al. Infrainguinal arterial reconstruction for claudication: Is it worth
the risk? An analysis of 409 procedures. J Vasc Surg 1999;29:259-69.
2. Fujioka K, Esato K, Zempo N, Katoh T, Fujimura Y, Yoshimura K.
Arterial reconstruction: Justified for patients with intermittent claudi-
cation? World J Surg 1998;22:1039-42.
3. Johnston KW. Femoral and popliteal arteries: Reanalysis of results of
balloon angioplasty. Radiology 1992;183:767-71.
4. Matsi PJ, Manninen HI, Vanninen RL, Suhonen MT, Oksala I, Laakso
M, et al. Femoropopliteal angioplasty in patients with claudication:
Primary and secondary patency in 140 limbs with 1-3 years follow-up.
Radiology 1994;191:727-33.
JOURNAL OF VASCULAR SURGERY
April 2003814 Ja¨mse´n et al
5. Matsi PJ, Manninen HI, Soder HK, Mustonen P, Kouri J. Percutaneous
transluminal angioplasty in femoral artery occlusions: Primary and long-
term results in 107 claudicant patients using femoral and popliteal
catheterization techniques. Clin Radiol 1995;50:237-44.
6. Wolf GL, Wilson SE, Cross AP, Deupree RH, Stason WB. Surgery or
balloon angioplasty for peripheral vascular disease: A randomized clin-
ical trial. Principal investigators and their Associates of Veterans Admin-
istration Cooperative Study Number 199. J Vasc Intervent Radiol
1993;4:639-48.
7. Kalman PG, Johnston KW, Sniderman KW. Indications and results of
balloon angioplasty for arterial occlusive lesions. World J Surg 1996;20:
630-4.
8. Hunink MG, Donaldson MC, Meyerovitz MF, Polak JF, Whittemore
AD, Kandarpa K, et al. Risks and benefits of femoropopliteal percuta-
neous balloon angioplasty. J Vasc Surg 1993;17:183-94.
9. Hunink MG, Wong JB, Donaldson MC, Meyerovitz MF, de Vries J,
Harrington DP. Revascularization for femoropopliteal disease: A deci-
sion and cost-effectiveness analysis. JAMA 1995;274:165-71.
10. Martin DR, Katz SG, Kohl RD, Qian D. Percutaneous transluminal
angioplasty of infrainguinal vessels. Ann Vasc Surg 1999;13:184-7.
11. Stanley B, Teague B, Raptis S, Taylor DJ, Berce M. Efficacy of balloon
angioplasty of the superficial femoral artery and popliteal artery in the
relief of leg ischemia. J Vasc Surg 1996;23:679-85.
12. Jensen LP. Intermittent claudication: Conservative treatment, endovas-
cular repair or open surgery for femoropopliteal disease. Ann Chir
Gynaecol 1998;87:137-40.
13. Becquemin JP, Cavillon A, Allaire E, Haiduc F, Desgranges P. Iliac and
femoropopliteal lesions: Evaluation of balloon angioplasty and classical
surgery. J Endovasc Surg 1995;2:42-50.
14. Schneider PA, Abcarian PW, Ogawa DY, Leduc JR, Wright PW. Should
balloon angioplasty and stents have any role in operative intervention
for lower extremity ischemia? Ann Vasc Surg 1997;11:574-80.
15. Second European Consensus Document on chronic critical leg isch-
emia. Circulation 1991;84:IV1-26.
16. Management of peripheral arterial disease (PAD). TransAtlantic Inter-
Society Consensus (TASC). Section D: Chronic critical limb ischaemia.
Eur J Vasc Endovasc Surg 2000;19(suppl A):S144-243.
17. Matsi PJ, Manninen HI, Suhonen MT, Pirinen AE, Soimakallio S.
Chronic critical lower-limb ischemia: Prospective trial of angioplasty
with 1-36 months follow-up. Radiology 1993;188:381-7.
18. Ahn SS, Rutherford RB, Becker GJ, Comerota AJ, Johnston KW,
McClean GK, et al. Reporting standards for lower extremity arterial
endovascular procedures. Society for Vascular Surgery/International
Society for Cardiovascular Surgery. J Vasc Surg 1993;17:1103-7.
19. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et
al. Recommended standards for reports dealing with lower extremity
ischemia: Revised version. J Vasc Surg 1997;26:517-38.
20. Feinglass J, McCarthy WJ, Slavensky R, Manheim LM, Martin GJ.
Functional status and walking ability after lower extremity bypass graft-
ing or angioplasty for intermittent claudication: Results from a prospec-
tive outcomes study. J Vasc Surg 2000;31:93-103.
21. Gelin J, Jivegard L, Taft C, Karlsson J, Sullivan M, Dahllof AG, et al.
Treatment efficacy of intermittent claudication by surgical intervention,
supervised physical exercise training compared to no treatment in
unselected randomised patients. I: One year results of functional and
physiological improvements. Eur J Vasc Endovasc Surg 2001;22:107-
13.
22. Whyman MR, Fowkes FG, Kerracher EM, Gillespie IN, Lee AJ, Hou-
sley E, et al. Is intermittent claudication improved by percutaneous
transluminal angioplasty? A randomized controlled trial. J Vasc Surg
1997;26:551-7.
23. Taylor L, Porter J. Natural history and nonoperative treatment of
chronic lower extremity ischemia. In: Rutherford RB, editor. Vascular
surgery. 4th edition. Philadelphia: WB Saunders; 1996.
24. Management of peripheral arterial disease (PAD). TransAtlantic Inter-
Society Consensus (TASC). Section B: Intermittent claudication. Eur J
Vasc Endovasc Surg 2000;19(suppl A):S47-114.
25. Clark TW, Groffsky JL, Soulen MC. Predictors of long-term patency
after femoropopliteal angioplasty: Results from the STAR registry. J
Vasc Intervent Radiol 2001;12:923-33.
26. Avino AJ, Bandyk DF, Gonsalves AJ, Johnson BL, Black TJ, Zwiebel
BR, et al. Surgical and endovascular intervention for infrainguinal vein
graft stenosis. J Vasc Surg 1999;29:60-71.
27. Goh RH, Sniderman KW, Kalman PG. Long-term follow-up of man-
agement of failing in situ saphenous vein bypass grafts using endovas-
cular intervention techniques. J Vasc Interv Radiol 2000;11:705-12.
28. Karch LA, Mattos MA, Henretta JP, McLafferty RB, Ramsey DE,
Hodgson KJ. Clinical failure after percutaneous transluminal angio-
plasty of the superficial femoral and popliteal arteries. J Vasc Surg
2000;31:880-7.
29. Loftus IM, Reid A, Thompson MM, London NJ, Bell PR, Naylor AR.
The increasing workload required to maintain infrainguinal bypass graft
patency. Eur J Vasc Endovasc Surg 1998;15:337-41.
30. Jamsen T, Tulla H, Manninen H, Raisanen H, Lahtinen S, Aittola V, et
al. Results of infrainguinal bypass surgery: An analysis of 263 consecu-
tive operations. Ann Chir Gynaecol 2001;90:92-9.
31. Capek P, McLean GK, Berkowitz HD. Femoropopliteal angioplasty:
Factors influencing long-term success. Circulation 1991;83:I70-80.
32. Soder HK, Manninen HI, Jaakkola P, Matsi PJ, Rasanen HT, Kaukanen
E, et al. Prospective trial of infrapopliteal artery balloon angioplasty for
critical limb ischemia: Angiographic and clinical results. J Vasc Interv
Radiol 2000;11:1021-31.
33. Varty K, Bolia A, Naylor AR, Bell PR, London NJ. Infrapopliteal
percutaneous transluminal angioplasty: A safe and successful procedure.
Eur J Vasc Endovasc Surg 1995;9:341-5.
34. Hertzer NR. The natural history of peripheral vascular disease: Impli-
cations for its management. Circulation 1991;83:I12-9.
Submitted Mar 21, 2002; accepted Oct 8, 2002.
Additional material for this article may be found online
at www.mosby.com/jvs.
JOURNAL OF VASCULAR SURGERY
Volume 37, Number 4 Ja¨mse´n et al 815
